Publications scientifiques en 2009

Depuis le 02/06/2023

  1. Factors associated with choice of psychotropic drugs used for intentional drug overdose.
    Tournier M, Grolleau A, Cougnard A, Molimard M, Verdoux H.
    Eur Arch Psychiatry Clin Neurosci. 2009
  2. Impact of antidepressants on the risk of suicide in patients with depression in real-life conditions: a decision analysis model.
    Cougnard A, Verdoux H, Grolleau A, Moride Y, Bégaud B, Tournier M.
    Psychol Med. 2009
  3. The risk of cognitive impairment in older community-dwelling women after benzodiazepine use.
    Lagnaoui R, Tournier M, Moride Y, Wolfson C, Ducruet T, Bégaud B, Moore N.
    Age Ageing. 2009
  4. The CADEUS study: burden of nonsteroidal anti-inflammatory drug (NSAID) utilization for musculoskeletal disorders in blue collar workers.
    Rossignol M, Abouelfath A, Lassalle R, Merlière Y, Droz C, Bégaud B, Depont F, Moride Y, Blin P, Moore N, Fourrier-Réglat A.
    Br J Clin Pharmacol. 2009
  5. Comparison of health insurance claims and patient interviews in assessing drug use: data from the Three-City (3C) Study.
    Noize P, Bazin F, Dufouil C, Lechevallier-Michel N, Ancelin ML, Dartigues JF, Tzourio C, Moore N, Fourrier-Réglat A.
    Pharmacoepidemiol Drug Saf. 2009
  6. Modalités et évolution de la prescription d'olanzapine : résultats de l'étude de cohorte ECOL.
    Gasquet I, Flandre P, Heurtebize N, Deal C, Perrin E, Chartier F, Fourrier-Réglat A.
    Encephale. 2009
  7. Oral diosmectite reduces stool output and diarrhea duration in children with acute watery diarrhea.
    Dupont C, Foo JL, Garnier P, Moore N, Mathiex-Fortunet H, Salazar-Lindo E, Peru and Malaysia Diosmectite Study Groups.
    Clin Gastroenterol Hepatol. 2009
  8. The prognostic impact of psychotropic drugs in intentional drug overdose.
    Tournier M, Grolleau A, Cougnard A, Verdoux H, Molimard M.
    Pharmacopsychiatry. 2009
  9. Bayesian pharmacovigilance signal detection methods revisited in a multiple comparison setting.
    Ahmed I, Haramburu F, Fourrier-Réglat A, Thiessard F, Kreft-Jais C, Miremont-Salamé G, Bégaud B, Tubert-Bitter P.
    Stat Med. 2009
  10. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX, Molimard M.
    Leuk Res. 2009
  11. Drug interactions between inhaled corticosteroids and enzymatic inhibitors.
    Daveluy A, Raignoux C, Miremont-Salamé G, Girodet PO, Moore N, Haramburu F, Molimard M.
    Eur J Clin Pharmacol. 2009
  12. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.
    Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX.
    Leukemia. 2009
  13. The impact of medicinal drugs on traffic safety: a systematic review of epidemiological studies.
    Orriols L, Salmi LR, Philip P, Moore N, Delorme B, Castot A, Lagarde E.
    Pharmacoepidemiol Drug Saf. 2009
  14. Effect of date of drug marketing on disproportionality measures in pharmacovigilance: the example of suicide with SSRIs using data from the UK MHRA.
    Pariente A, Daveluy A, Laribière-Bénard A, Miremont-Salame G, Bégaud B, Moore N.
    Drug Saf. 2009
  15. No obvious extra cardiovascular risk associated with low-dose NSAIDs.
    Moore N.
    Clin Pharmacol Ther. 2009
  16. Medicines submitted to narcotics regulations in France, 1992-2007.
    Baumevieille M, Daveluy A, Maurain C, Bégaud B, Haramburu F.
    Fundam Clin Pharmacol. 2009
  17. The self-reported Montgomery-Asberg Depression Rating Scale is a useful evaluative tool in Major Depressive Disorder.
    Fantino B, Moore N.
    BMC Psychiatry. 2009
  18. Homoeopathic product licence. Being useless may be useful.
    Moore N.
    BMJ. 2009
  19. Pharmacoepidemiology of psychotropic drugs: examples of current research challenges on major public health issues.
    Verdoux H, Tournier M, Bégaud B.
    Epidemiol Psichiatr Soc. 2009
  20. The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
    Blazejewski S, Georges A, Forest K, Corcuff JB, Abouelfath A, Girodet PO, Kamagate M, Jacquet A, Pillet O, Bordenave L, Moore N.
    Fundam Clin Pharmacol. 2009
  21. Abnormal Savda Munziq, an Herbal Preparation of Traditional Uighur Medicine, may Prevent 1,2-dimethylhydrazine-induced Rat Colon Carcinogenesis.
    Yusup A, Upur H, Umar A, Berke B, Yimit D, Lapham JC, Moore N, Cassand P.
    Evid Based Complement Alternat Med. 2009
  22. Gender and interindividual variability in pharmacokinetics.
    Nicolas JM, Espie P, Molimard M.
    Drug Metab Rev. 2009
  23. Pharmacokinetics in special populations.
    Poggesi I, Benedetti MS, Whomsley R, Le Lamer S, Molimard M, Watelet JB.
    Drug Metab Rev. 2009
  24. NSAIDs discontinuation and myocardial infarction.
    Salvo F, Pariente A, Noize P, Fourrier-Réglat A, Moore N.
    J Thromb Haemost. 2009
  25. Influence of ethnic origin (Asian v. Caucasian) and background diet on the bioavailability of dietary isoflavones.
    Vergne S, Sauvant P, Lamothe V, Chantre P, Asselineau J, Perez P, Durand M, Moore N, Bennetau-Pelissero C.
    Br J Nutr. 2009
  26. Inappropriate medication use and risk of falls--a prospective study in a large community-dwelling elderly cohort.
    Berdot S, Bertrand M, Dartigues JF, Fourrier A, Tavernier B, Ritchie K, Alpérovitch A.
    BMC Geriatr. 2009
  27. Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study.
    Carrière I, Fourrier-Reglat A, Dartigues JF, Rouaud O, Pasquier F, Ritchie K, Ancelin ML.
    Arch Intern Med. 2009
  28. Value of post-registration studies for reimbursement renewal.
    Molimard M, Bamberger M, Vray M.
    Therapie. 2009
  29. A therapeutic drug monitoring algorithm for refining the imatinib trough level obtained at different sampling times.
    Wang Y, Chia YL, Nedelman J, Schran H, Mahon FX, Molimard M.
    Ther Drug Monit. 2009
  30. The EU-ADR project: preliminary results and perspective.
    Trifiro G, Fourrier-Reglat A, Sturkenboom MC, Díaz Acedo C, Van Der Lei J, EU-ADR Group.
    Stud Health Technol Inform. 2009
  31. A semantic approach for the homogeneous identification of events in eight patient databases: a contribution to the European eu-ADR project.
    Avillach P, Mougin F, Joubert M, Thiessard F, Pariente A, Dufour JC, Trifirò G, Polimeni G, Catania MA, Giaquinto C, Mazzaglia G, Baio G, Herings R, Gini R, Hippisley-Cox J, Molokhia M, Pedersen L, Fourrier-Réglat A, Sturkenboom M, Fieschi M.
    Stud Health Technol Inform. 2009
  32. Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?
    Trifirò G, Pariente A, Coloma PM, Kors JA, Polimeni G, Miremont-Salamé G, Catania MA, Salvo F, David A, Moore N, Caputi AP, Sturkenboom M, Molokhia M, Hippisley-Cox J, Acedo CD, van der Lei J, Fourrier-Reglat A, EU-ADR group.
    Pharmacoepidemiol Drug Saf. 2009
  33. Guidelines for submitting adverse event reports for publication.
    Kelly W, Arellano F, Barnes J, Bergman U, Edwards R, Fernandez A, Freedman S, Goldsmith D, Huang K, Jones J, McLeay R, Moore N, Stather R, Trenque T, Troutman W, van Puijenbroek E, Williams F, Wise R, International Society of Pharmacoepidemiology, International Society of Pharmacovigilance.
    Therapie. 2009
  34. Hepatitis B vaccine and the risk of CNS inflammatory demyelination in childhood.
    Lièvre M, Members of Epidemiology Working Group of French Pharmacovigilance Commission, Costagliola D, Evans S, Fourrier A, Imbs JL, Levy-Bruhl D, Merle L, Micallef J, Oger E.
    Neurology. 2009
  35. Patterns of laxative use in self-medication.
    Théophile H, Miremont-Salamé G, Abouelfath A, Bégaud B, Haramburu F.
    Ann Pharmacother. 2009
  36. Phytalgic, a food supplement, vs placebo in patients with osteoarthritis of the knee or hip: a randomised double-blind placebo-controlled clinical trial.
    Jacquet A, Girodet PO, Pariente A, Forest K, Mallet L, Moore N.
    Arthritis Res Ther. 2009
  37. Risk of death related to psychotropic drug use in older people during the European 2003 heatwave: a population-based case-control study.
    Nordon C, Martin-Latry K, de Roquefeuil L, Latry P, Bégaud B, Falissard B, Rouillon F, Verdoux H.
    Am J Geriatr Psychiatry. 2009
  38. Prevalence and preventability of adverse drug events in a teaching hospital: a cross-sectional study.
    Benkirane R, Pariente A, Achour S, Ouammi L, Azzouzi A, Soulaymani R.
    East Mediterr Health J. 2009
  39. Epidemiology of COPD.
    Raherison C, Girodet PO.
    Eur Respir Rev. 2009